<DOC>
	<DOCNO>NCT02953639</DOCNO>
	<brief_summary>This multicenter study assess effect 24 week basmisanil treatment cognition function stable CIAS participant treat antipsychotic .</brief_summary>
	<brief_title>A Study Evaluate Effects Basmisanil Participants With Cognitive Impairment Associated With Schizophrenia ( CIAS ) Treated With Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosis schizophrenia type utilize Mini International Neuropsychiatric Interview ( MINI ) diagnostic statistical manual mental disorder , fifth edition , ( DSM5 ) direct clinical assessment , family informant past medical record Evidence stability symptom 3 month screen , ( i.e . ) , without hospitalization schizophrenia increase level psychiatric care due worsen symptom schizophrenia Participants schizophrenia clinical symptom severity define follow : hallucinatory behavior item score less equal ( &lt; /= ) 5 delusion item score &lt; /= 5 PANSS Participants stable regimen antipsychotic therapy least 3 month screen receive two antipsychotic Participants current DSM5 diagnosis schizophrenia include bipolar disorder , schizoaffective disorder major depressive disorder ( MDD ) Clinically significant neurological illness significant head trauma affect cognitive function , judgment principal investigator Full scale intelligence quotient ( FSIQ ) &lt; 70 Wechsler Abbreviated Scale Intelligence ( WASIII ) screen Positive result screen hepatitis B ( HBV ) , hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) 1 2 Moderate severe substance use disorder ( nicotine caffeine ) , define DSM5 , within last 12 month Suicide attempt within one year currently risk suicide opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>